Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Sep 13, 2019 12:17pm
194 Views
Post# 30124072

Brillant strategy...

Brillant strategy...In the Aug 14, 2019 PressRelease SZLS said " The company has initiated(set in motion) a contract with a large Health System to improve patients compliance with cancer screening."

This Quote say's a lots about SZLS strategy.
Doctors are sometime very convervative about the way they test patients. If for a doctor Exas:Us cologuard poop test work fine, the doctor will not try to convince a patient to switch to a blood test (SZLS).The same goes for a Colonoscopy.

What SZLS is telling doctors is SZLS(for now) is not trying to replace Exas:Us Cologuard or a Colonoscopy, SZLS is simply giving doctors an alternative for the non-compliant patients who are not interested to pay $600.USD to poop in a box, or patients that will undergo an expensive colonoscopy (average price $2,000USD) only if they really have to.https://mdsave.com/procedures/colonoscopy/d783fdcd

It's a Win Win situation, doctors keep their prerogative to use Exas:Us Cologuard or a colonoscopy and at the same time they have an alternative (Colonsentry) that will test the non-compliant patients for treatments if necessary and keep these patients in their office (more patients = more money).

Brillant strategy...

Bullboard Posts